Cytochrome P450 2D6 (CYP2D6) genotype–guided opioid prescribing is limited. The purpose of this type 2 hybrid implementation-effectiveness trial was to evaluate the feasibility of clinically implementing CYP2D6-guided postsurgical pain management and determine that such an approach did not worsen pain control.
Adults undergoing total joint arthroplasty were randomized 2:1 to genotype-guided or usual pain management. For participants in the genotype-guided arm with a CYP2D6 poor (PM), intermediate (IM), or ultrarapid (UM) metabolizer phenotype, recommendations were to avoid hydrocodone, tramadol, codeine, and oxycodone. The primary endpoints were feasibility metrics and opioid use; pain intensity was a secondary endpoint. Effectiveness outcomes were collected 2 weeks postsurgery.
Of 282 patients approached, 260 (92%) agreed to participate. In the genotype-guided arm, 20% had a high-risk (IM/PM/UM) phenotype, of whom 72% received an alternative opioid versus 0% of usual care participants (p < 0.001). In an exploratory analysis, there was less opioid consumption (200 [104–280] vs. 230 [133–350] morphine milligram equivalents; p = 0.047) and similar pain intensity (2.6 ± 0.8 vs. 2.5 ± 0.7; p = 0.638) in the genotype-guided vs. usual care arm, respectively.
Implementing CYP2D6 to guide postoperative pain management is feasible and may lead to lower opioid use without compromising pain control.
Subscribe to Journal
Get full journal access for 1 year
only $41.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Data set and code available upon request.
Gereau, R. W. T. et al. A pain research agenda for the 21st century. J. Pain. 15, 1203–1214 (2014).
Hoots B. E. et al. 2018 Annual surveillance report of drug-related risks and outcomes-United States. Surveillance Special Report. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Published August 31, 2018. Accessed May 30, 2020.
Levy, B., Paulozzi, L., Mack, K. A. & Jones, C. M. Trends in opioid analgesic-prescribing rates by specialty, U.S., 2007-2012. Am. J. Prev. Med. 49, 409–413 (2015).
Aubrun, F., Langeron, O., Quesnel, C., Coriat, P. & Riou, B. Relationships between measurement of pain using visual analog score and morphine requirements during postoperative intravenous morphine titration. Anesthesiology. 98, 1415–1421 (2003).
Abdel Shaheed, C., Maher, C. G., Williams, K. A., Day, R. & McLachlan, A. J. Efficacy, tolerability, and dose-dependent effects of opioid analgesics for low back pain: a systematic review and meta-analysis. JAMA Intern. Med. 176, 958–968 (2016).
Kalso, E., Edwards, J. E., Moore, R. A. & McQuay, H. J. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 112, 372–380 (2004).
Lopes, G. S. et al. Sex differences in associations between CYP2D6 phenotypes and response to opioid analgesics. Pharmacogenomics Pers. Med. 13, 71–79 (2020).
Crews, K. R. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin. Pharmacol. Ther. 95, 376–382 (2014).
Volpe, D. A. et al. Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs. Regul Toxicol. Pharmacol. 59, 385–390 (2011).
Ultram (tramadol) [package insert]. Titusville, NJ: Janssen Pharmaceutical Companies; 2019.
Davis, M. P. et al. Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Support Care Cancer 11, 84–92 (2003).
Smith, D. M. et al. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. Genet. Med. 21, 1842–1850 (2019).
Ciszkowski, C., Madadi, P., Phillips, M. S., Lauwers, A. E. & Koren, G. Codeine, ultrarapid-metabolism genotype, and postoperative death. N. Engl. J. Med. 361, 827–828 (2009).
Gasche, Y. et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N. Engl. J. Med. 351, 2827–2831 (2004).
Koren, G., Cairns, J., Chitayat, D., Gaedigk, A. & Leeder, S. J. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet. 368, 704 (2006).
Kapil, R. P. et al. Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. Clin. Ther. 37, 2286–2296 (2015).
Monte, A. A. et al. The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness. Acad. Emerg. Med. 21, 879–885 (2014).
Curran, G. M., Bauer, M., Mittman, B., Pyne, J. M. & Stetler, C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med. Care 50, 217–226 (2012).
Loudon, K. et al. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 350, h2147 (2015).
Gaedigk, A. et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83, 234–242 (2008).
Hicks, J. K., Swen, J. J. & Gaedigk, A. Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization. Curr. Drug. Metab. 15, 218–232 (2014).
Borges, S. et al. Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J. Clin. Pharmacol. 50, 450–458 (2010).
Kim, K. M. et al. Pharmacogenetics and healthcare outcomes in patients with chronic heart failure. Eur. J. Clin. Pharmacol. 68, 1483–1491 (2012).
Mosley, S. A. et al. Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial. Contemp. Clin. Trials 68, 7–13 (2018).
Adams, E. H. et al. A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain. J. Pain Symptom Manage. 31, 465–476 (2006).
Preston, K. L., Jasinski, D. R. & Testa, M. Abuse potential and pharmacological comparison of tramadol and morphine. Drug Alcohol Depend. 27, 7–17 (1991).
Cella, D. et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med. Care. 45(5 Suppl 1), S3–S11 (2007).
Dowell, D., Haegerich, T. M. & Chou, R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. 315, 1624–1645 (2016).
Virtanen, P. et al. SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat. Methods. https://doi.org/10.1038/s41592-019-0686-2 (2020).
Han, B. et al. Prescription opioid use, misuse, and use disorders in U.S. adults: 2015 National Survey on Drug Use and Health. Ann. Intern. Med. 167, 293–301 (2017).
Dai, F. et al. Integration of pain score and morphine consumption in analgesic clinical studies. J. Pain. 14, 767–777 (2013).
Brummett, C. M. et al. New persistent opioid use after minor and major surgical procedures in US adults. JAMA Surg. 152, e170504 (2017).
Ringwalt, C. et al. Differential prescribing of opioid analgesics according to physician specialty for Medicaid patients with chronic noncancer pain diagnoses. Pain Res. Manag. 19, 179–185 (2014).
Wick, E. C., Grant, M. C. & Wu, C. L. Postoperative Multimodal Analgesia Pain Management With Nonopioid Analgesics and Techniques: A Review. JAMA surgery 152, 691–697 (2017).
Sjoveian, A. K. H. & Leegaard, M. Hip and knee arthroplasty - patient’s experiences of pain and rehabilitation after discharge from hospital. Int J Orthop Trauma Nurs 27, 28–35 (2017).
Jhun, E. H. et al. Pharmacogenomic considerations for medications in the perioperative setting. Pharmacogenomics. 20, 813–827 (2019).
Truong, T. M. et al. The ImPreSS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care. Clin Pharmacol Ther 106, 1179–1183 (2019).
Seripa, D. et al. Role of CYP2D6 Polymorphisms in the Outcome of Postoperative Pain Treatment. Pain Med (Malden, Mass) 16, 2012–2023 (2015).
Dong, H. et al. Effect of the CYP2D6 gene polymorphism on postoperative analgesia of tramadol in Han nationality nephrectomy patients. Eur J Clin Pharmacol 71, 681–686 (2015).
Stamer, U. M. et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain. 105, 231–238 (2003).
Slanar, O. et al. Tramadol efficacy in patients with postoperative pain in relation to CYP2D6 and MDR1 polymorphisms. Bratisl Lek Listy 113, 152–155 (2012).
This work was supported by the University of Florida Clinical and Translational Science Institute, which is supported in part by the NIH National Center for Advancing Translational Sciences under award number UL1TR001427 and University of Florida Health Shands. Work by C.D.T. was supported by T32 HG008958. Research reported in this publication was also supported by NIH/NHGRI (U01 HG 007269). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Y.G., R.B.F., J.A.J., and L.H.C. have received research funding from the National Institutes of Health. P.S. receives support from University of Florida Health Pathology Laboratories. C.F.G. is a stockholder for ROMTech. The other authors declare no competing interests.
All study participants provided written, informed consent. The study was approved by the University of Florida Institutional Review Board, and all procedures were in accordance with the ethical standards of the Declaration of Helsinki and registered in ClinicalTrials.gov (NCT03534063).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Thomas, C.D., Parvataneni, H.K., Gray, C.F. et al. A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain management. Genet Med (2021). https://doi.org/10.1038/s41436-020-01050-4